Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 140-148

  Stoetzer, Oliver J ^a   Fersching, Debora M I ^b   Salat, Christoph ^a   Steinkohl, Oliver ^c   Gabka, Christian J ^c   Hamann, Ulrich ^d   Braun, Michael ^d   Feller, Axel Mario ^e   Heinemann, Volker ^b   Siegele, Barbara ^b   Nagel, Dorothea ^b   Holdenrieder, Stefan ^b,f  

^a Haematology and Oncology Outpatient Cancer Care Center   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Klinikum Dritter Orden   (Germany)

^d Red Cross Breast Cancer Center II   (Germany)

^e Breast Cancer Center Dr Geisenhofer   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Apoptotic biomarkers; Breast cancer; Cytokeratin fragments; Neoadjuvant chemotherapy; Nucleosomes; Survivin

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN 18; DEOXYRIBONUCLEASE; DOCETAXEL; EPIRUBICIN; PACLITAXEL; SURVIVIN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOSOME; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84878965534     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.013     Document Type: Article

References (45)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J. Cancer statistics 2007. CA Cancer J. Clin. 2007, 57:43-66.
2. Ozols R.F., Herbst R.S., Colson Y.L., Gralow J., Bonner J., Curran W.J., Eisenberg B.L., Ganz P.A., Kramer B.S., Kris M.G., Markman M., Mayer R.J. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 2006, 25(2007):146-162.
3. Bundret N.J. Prognostic and predictive factors in breast cancer. Cancer Trial Rev. 2001, 27:137-142.
4. EBCTCG Effects of chemotherapy and hormonel therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised treals. Early Breast Cancer Trialists Collaborative Group. Lancet 2005, 365:1687-1717.
5. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-years results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 2001, 30:96-102.
6. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., Pusztai L., Green M.C., Arun B.K., Giordano S.H., Cristofanilli M., Frye D.K. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 2005, 23:3676-3685.
7. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Untch M., von Minckwitz G. Recommendations from an expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 2006, 24:1940-1949.
8. Beachy S.H., Repasky E.A. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol. Immunother. 2008, 57:759-775.
9. Holdenrieder S., Stieber P. Apoptotic markers in cancer. Clin. Biochem. 2004, 37:605-617.
10. Holdenrieder S., Stieber P. Clinical use of circulating nucleosomes. Crit. Rev. Lab. Med. Sci. 2009, 46:1-24.
11. Holdenrieder S., Stieber P., von Pawel J., Raith H., Nagel D., Feldmann K., Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced nonsmall cell lung cancer. Clin. Cancer Res. 2004, 10:5981-5987.
12. Holdenrieder S., Stieber P., von Pawel J., Raith H., Nagel D., Feldmann K., Seidel D. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann. NY. Acad. Sci. 2006, 1075:244-275.
13. Holdenrieder S., Stieber P., Bodenmueller H., Busch M., Fertig G., Fuerst H., Schalhorn A., Schmeller N., Untch M., Seidel D. Nucleosomes in serum of patients with benign and malignant diseases. Int. J. Cancer 2001, 95:114-120.
14. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., Siakavara M., Wagner H., Feldmann K., Hoffmann H., Raith H., Nagel D., Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin. Cancer Res. 2008, 14:7813-7821.
15. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., Siakavara M., Wagner H., Feldmann K., Hoffmann H., Raith H., Nagel D., Stieber P. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63:128-135.
16. Kremer A., Wilkowski R., Holdenrieder S., Nagel D., Stieber P., Seidel D. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol. 2005, 26:44-49.
17. Kremer A., Holdenrieder S., Stieber P., Wilkowski R., Nagel D., Seidel D. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumor Biol. 2006, 27:235-242.
18. Economidou-Karaoglou A., Brasseur F., Lans M., Taper H.S., Roberfroid M.B. Variations in serum alkaline DNase activity in rats during growth and treatment of tumors sensitive or resistant to therapy. Int. J. Cancer 1989, 43:956-959.
19. Leers M.P.G., Koelgen W., Bjoerklund V., Bergman T., Tribbick G., Persson B., Bjoerklund P., Ramaekers F.C.S., Bjoerklund B., Nap M., Joernvall H., Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 1999, 187:567-572.
20. Linder S. Cytokeratin markers come of age. Tumor Biol. 2007, 28:189-195.
21. Ueno T., Toi M., Biven K., Bando H., Ogawa T., Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur. J. Cancer 2003, 39:769-774.
22. Koelink P.J., Lamers C.B., Hommes D.W., Verspaget H.W. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 2009, 9:88.
23. Ulukaya E., Yilmaztepe A., Akgoz S., Linder S., Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007, 56:399-404.
24. Ozturk B., Coskun U., Sancak B., Yaman E., Buyukberber S., Benekli M. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int. Immunopharmacol. 2009, 9:645-648.
25. Kramer G., Erdal H., Mertens H.J., Nap M., Mauermann J., Steiner G., Marberger M., Biven K., Shoshan M.C., Linder S. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004, 64:1751-1756.
26. Ward T.H., Cummings J., Dean E., Greystoke A., Hou J.M., Backen A., Ranson M., Dive C. Biomarkers of apoptosis. Br. J. Cancer 2008, 99:841-846.
27. Kren L., Brazdil J., Hermanova M., Goncharuk V.N., Kallakury B.V., Kaur P., Ross J.S. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl. Immunohistochem. Mol. Morphol. 2004, 12:44-49.
28. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000, 92:205-216.
29. Holdenrieder S., Stieber P., Bodenmueller H., Fertig G., Fuerst H., Schmeller N., Untch M., Seidel D. Nucleosomes in serum as a marker for cell death. Clin. Chem. Lab. Med. 2001, 39:596-605.
30. Stoetzer O.J., Fersching D.I.M., Salat C., Steinkohl O., Gabka C.J., Hamann U., Braun M., Feller A.M., Heinemann V., Siegele B., Nagel D., Holdenrieder S. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumor Biol. 2013, 34:81-90.
31. Barak V., Goike H., Panaretakis K.W., Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 2004, 37:529-540.
32. Holdenrieder S., Nagel D., Stieber P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomark. 2010, 6:179-190.
33. Barak V., Holdenrieder S., Nisman B., Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark. 2010, 6:191-196.
34. Kumar S., Guleria R., Singh V., Bharti A.C., Mohan A., Das B.C. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin. Lung Cancer 2010, 11:36-44.
35. Kohles N., Nagel D., Juengst D., Durner J., Stieber P., Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer 2011, 11:202.
36. Fahmueller Y., Nagel D., Hoffmann R.T., Tatsch K., Jakobs T., Stieber P., Holdenrieder S. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing selective internal radiation therapy. BMC Cancer 2012, 12:5.
37. Gautschi O., Bigosch C., Huegli B., Jermann M., Marx A., Chasse E., Ratschiller D., Weder W., Joerger M., Betticher D.C., Stahel R.A., Ziegler A. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J. Clin. Oncol. 2004, 22:4157-4164.
38. Holdenrieder S., Stieber P., Chan L.Y.S., Geiger S., Kremer A., Nagel D., Lo Y.M. Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin. Chem. 2005, 51:1544-1546.
39. Molina R., Holdenrieder S., Auge J.M., Schalhorn A., Hatz R.A., Stieber P. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark. 2010, 6:163-178.
40. Sheard M.A., Vojtesek B., Simickova M., Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J. Cell Biochem. 2002, 85:670-677.
41. Guney N., Soydine H.O., Derin D., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E. Serum and urine survivin levels in breast cancer. Med. Oncol. 2006, 23:335-339.
42. Rexhepaj E., Jirstrom K., O'Connor D.P., O'Brien S.L., Landberg G., Duffy M.J., Brennan D.J., Gallagher W.M. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer 2010, 10:639.
43. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brunner N., Chan D.W., Babaian R., Bast R.C., Dowell B., Esteva F.J., Haglund C., Harbeck N. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 2008, 54:11-79.
44. Molina R., Barak V., van Dalen A., Duffy M.J., Einarsson R., Gion M., Goike H., Lamerz R., Nap M., Sölétormos G., Stieber P. Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumor Biol. 2005, 26:281-293.
45. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 2006, 100:229-235.